EU/3/14/1348
Table of contents
About
On 15 October 2014, orphan designation (EU/3/14/1348) was granted by the European Commission to Stemgen S.p.A., Italy, for recombinant human bone morphogenetic protein 4 for the treatment of glioma.
The sponsor’s address was updated in November 2020.
Key facts
Active substance |
Recombinant human bone morphogenetic protein 4
|
Disease / condition |
Treatment of glioma
|
Date of first decision |
15/10/2014
|
Outcome |
Positive
|
EU designation number |
EU/3/14/1348
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
STEMGEN S.p.A.
Viale Bianca Maria 25
20122 Milano
Italy
Tel: + 39 344 0992434
E-mail: zaccarini@stemgen.net
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.